Skip to main content
Erschienen in: Supportive Care in Cancer 5/2008

01.05.2008 | Original Article

Constipation in cancer patients on morphine

verfasst von: Joanne Droney, Joy Ross, Sophy Gretton, Ken Welsh, Hiroe Sato, Julia Riley

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2008

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

Constipation is a significant problem in patients taking morphine for cancer pain. The aims of this study were (1) to assess the magnitude of constipation in this study cohort, (2) to analyse the constipation treatment strategies and (3) to look for evidence of inter-individual variation in both susceptibility to constipation and response to treatment with laxatives in this patient group.

Materials and methods

This was an observational study carried out in a tertiary referral cancer hospital. Two hundred seventy four patients were recruited to the study. All had a diagnosis of cancer and were on oral morphine for cancer pain. The main outcomes measured were subjective patient assessment of constipation severity in the preceding week and laxative use. Patients were asked to grade constipation in the preceding week on a four-point categorical scale: “not at all” (grade 0), “a little” (grade 1), “quite a bit” (grade 2) and “very much” (grade 3). Laxative dose groups (LDGs) were developed to assess laxative dosing.

Results

Constipation affects 72% of this cohort of patients. Constipation in this population is poorly managed. Eighty nine percent of constipated patients were on inadequate laxative therapy. Inter-individual variation in constipation on morphine exists: some patients do not experience constipation and do not need to take any laxatives, some patients do not experience constipation because they are taking laxatives and some patients experience constipation despite being on high dose laxatives. These three groups were compared in terms of cancer diagnosis, time on morphine, dose of morphine and other concomitant factors. No factor was identified to account for this inter-individual variation. Improvement in the clinical management of constipation is needed, with titration of laxatives according to individual patient need.

Conclusion

Constipation affects a large proportion of cancer patients taking oral morphine. Constipation in these patients is generally inadequately treated.
Literatur
1.
Zurück zum Zitat Bennett M, Cresswell H (2003) Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning. Palliat Med 17:418–422PubMedCrossRef Bennett M, Cresswell H (2003) Factors influencing constipation in advanced cancer patients: a prospective study of opioid dose, dantron dose and physical functioning. Palliat Med 17:418–422PubMedCrossRef
2.
Zurück zum Zitat British Medical Association, Royal Pharmaceutical Society of Great Britain (2007) British National Formulary. Bemrose Security Printing, Derby British Medical Association, Royal Pharmaceutical Society of Great Britain (2007) British National Formulary. Bemrose Security Printing, Derby
3.
Zurück zum Zitat Bruera E, Suarez-Almazor M, Velasco A, Bertolino M, MacDonald SM, Hanson J (1994) The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage 9:515–519PubMedCrossRef Bruera E, Suarez-Almazor M, Velasco A, Bertolino M, MacDonald SM, Hanson J (1994) The assessment of constipation in terminal cancer patients admitted to a palliative care unit: a retrospective review. J Pain Symptom Manage 9:515–519PubMedCrossRef
4.
Zurück zum Zitat Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542–2554PubMed Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, Mercadante S, Pasternak G, Ventafridda V (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542–2554PubMed
5.
Zurück zum Zitat Fallon MT, Hanks GW (1999) Morphine, constipation and performance status in advanced cancer patients. Palliat Med 13:159–160PubMedCrossRef Fallon MT, Hanks GW (1999) Morphine, constipation and performance status in advanced cancer patients. Palliat Med 13:159–160PubMedCrossRef
6.
Zurück zum Zitat Gibson RJ, Keefe DM (2006) Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 14:890–900PubMedCrossRef Gibson RJ, Keefe DM (2006) Cancer chemotherapy-induced diarrhoea and constipation: mechanisms of damage and prevention strategies. Support Care Cancer 14:890–900PubMedCrossRef
7.
Zurück zum Zitat Grond S, Zech D, Diefenbach C, Bischoff A (1994) Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 9:372–382PubMedCrossRef Grond S, Zech D, Diefenbach C, Bischoff A (1994) Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J Pain Symptom Manage 9:372–382PubMedCrossRef
8.
Zurück zum Zitat Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D, Reichman S (1996) Constipation: a different entity for patients and doctors. Fam Pract 13:156–159PubMedCrossRef Herz MJ, Kahan E, Zalevski S, Aframian R, Kuznitz D, Reichman S (1996) Constipation: a different entity for patients and doctors. Fam Pract 13:156–159PubMedCrossRef
9.
Zurück zum Zitat Holzer P (2004) Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 361:192–195PubMedCrossRef Holzer P (2004) Opioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humans. Neurosci Lett 361:192–195PubMedCrossRef
10.
Zurück zum Zitat Kurz A, Sessler DI (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63:649–671PubMedCrossRef Kurz A, Sessler DI (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63:649–671PubMedCrossRef
11.
Zurück zum Zitat Mancini I, Bruera E (1998) Constipation in advanced cancer patients. Support Care Cancer 6:356–364PubMedCrossRef Mancini I, Bruera E (1998) Constipation in advanced cancer patients. Support Care Cancer 6:356–364PubMedCrossRef
12.
Zurück zum Zitat Mancini IL, Hanson J, Neumann CM, Bruera ED (2000) Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 3:49–56PubMedCrossRef Mancini IL, Hanson J, Neumann CM, Bruera ED (2000) Opioid type and other clinical predictors of laxative dose in advanced cancer patients: a retrospective study. J Palliat Med 3:49–56PubMedCrossRef
13.
Zurück zum Zitat McMillan SC, Williams FA (1989) Validity and reliability of the Constipation Assessment Scale. Cancer Nurs 12:183–188PubMedCrossRef McMillan SC, Williams FA (1989) Validity and reliability of the Constipation Assessment Scale. Cancer Nurs 12:183–188PubMedCrossRef
14.
Zurück zum Zitat Miles C, Fellowes D, Goodman M, Wilkinson S (2006) Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev CD003448 Miles C, Fellowes D, Goodman M, Wilkinson S (2006) Laxatives for the management of constipation in palliative care patients. Cochrane Database Syst Rev CD003448
15.
Zurück zum Zitat Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11–18CrossRef Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11–18CrossRef
16.
Zurück zum Zitat Portenoy RK (1987) Constipation in the cancer patient: causes and management. Med Clin North Am 71:303–311PubMed Portenoy RK (1987) Constipation in the cancer patient: causes and management. Med Clin North Am 71:303–311PubMed
17.
Zurück zum Zitat Riechelmann RP, Krzyzanowska MK, O’carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer, 15(12):1407–1412PubMedCrossRef Riechelmann RP, Krzyzanowska MK, O’carroll A, Zimmermann C (2007) Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer, 15(12):1407–1412PubMedCrossRef
18.
Zurück zum Zitat Riley J, Ross JR, Rutter D, Wells AU, Goller K, Du BR, Welsh K (2006) No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 14:56–64PubMedCrossRef Riley J, Ross JR, Rutter D, Wells AU, Goller K, Du BR, Welsh K (2006) No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients. Support Care Cancer 14:56–64PubMedCrossRef
19.
Zurück zum Zitat Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, Du BR, Riley J (2005) Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 5:324–336PubMedCrossRef Ross JR, Rutter D, Welsh K, Joel SP, Goller K, Wells AU, Du BR, Riley J (2005) Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J 5:324–336PubMedCrossRef
20.
Zurück zum Zitat Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B (1992) A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 7:259–266PubMedCrossRef Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B (1992) A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 7:259–266PubMedCrossRef
21.
Zurück zum Zitat Schuit KW, Sleijfer DT, Meijler WJ, Otter R, Schakenraad J, van den Bergh FC, Meyboom-de JB (1998) Symptoms and functional status of patients with disseminated cancer visiting outpatient departments. J Pain Symptom Manage 16:290–297PubMedCrossRef Schuit KW, Sleijfer DT, Meijler WJ, Otter R, Schakenraad J, van den Bergh FC, Meyboom-de JB (1998) Symptoms and functional status of patients with disseminated cancer visiting outpatient departments. J Pain Symptom Manage 16:290–297PubMedCrossRef
22.
Zurück zum Zitat Sykes, N (2007) Methods for clinical research in constipation. internet. 21-6-2007. Ref Type: Electronic Citation Sykes, N (2007) Methods for clinical research in constipation. internet. 21-6-2007. Ref Type: Electronic Citation
23.
Zurück zum Zitat Sykes NP (1994) Current approaches to the management of constipation. Cancer Surv 21:137–146PubMed Sykes NP (1994) Current approaches to the management of constipation. Cancer Surv 21:137–146PubMed
24.
Zurück zum Zitat Sykes NP (1996) A volunteer model for the comparison of laxatives in opioid-related constipation. J Pain Symptom Manage 11:363–369PubMedCrossRef Sykes NP (1996) A volunteer model for the comparison of laxatives in opioid-related constipation. J Pain Symptom Manage 11:363–369PubMedCrossRef
25.
Zurück zum Zitat Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12:375–382PubMedCrossRef Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12:375–382PubMedCrossRef
26.
Zurück zum Zitat Sykes NP (2006) The pathogenesis of constipation. J Support Oncol 4:213–218PubMed Sykes NP (2006) The pathogenesis of constipation. J Support Oncol 4:213–218PubMed
27.
Zurück zum Zitat Talley NJ, Jones M, Nuyts G, Dubois D (2003) Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 98:1107–1111PubMedCrossRef Talley NJ, Jones M, Nuyts G, Dubois D (2003) Risk factors for chronic constipation based on a general practice sample. Am J Gastroenterol 98:1107–1111PubMedCrossRef
28.
Zurück zum Zitat The Royal Marsden (2002) Guidelines for Symptom Control The Royal Marsden (2002) Guidelines for Symptom Control
29.
Zurück zum Zitat Twycross RG, Harcourt J (1991) The use of laxatives at a palliative care centre. Palliative Medicine 5:27–33CrossRef Twycross RG, Harcourt J (1991) The use of laxatives at a palliative care centre. Palliative Medicine 5:27–33CrossRef
30.
Zurück zum Zitat Twycross RG, Wilcock A, Charlesworth S, Dickman A (2002) Palliative Care Formulary. Radcliffe Medical Press, London Twycross RG, Wilcock A, Charlesworth S, Dickman A (2002) Palliative Care Formulary. Radcliffe Medical Press, London
31.
Zurück zum Zitat Vainio A, Auvinen A (1996) Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 12:3–10PubMedCrossRef Vainio A, Auvinen A (1996) Prevalence of symptoms among patients with advanced cancer: an international collaborative study. Symptom Prevalence Group. J Pain Symptom Manage 12:3–10PubMedCrossRef
32.
Zurück zum Zitat Vanegas G, Ripamonti C, Sbanotto A, De CF (1998) Side effects of morphine administration in cancer patients. Cancer Nurs 21:289–297PubMedCrossRef Vanegas G, Ripamonti C, Sbanotto A, De CF (1998) Side effects of morphine administration in cancer patients. Cancer Nurs 21:289–297PubMedCrossRef
Metadaten
Titel
Constipation in cancer patients on morphine
verfasst von
Joanne Droney
Joy Ross
Sophy Gretton
Ken Welsh
Hiroe Sato
Julia Riley
Publikationsdatum
01.05.2008
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2008
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-007-0373-1

Weitere Artikel der Ausgabe 5/2008

Supportive Care in Cancer 5/2008 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.